Medical Device News Magazine

iRemedy Advises “Project Vaccinate” Program is Gaining Traction in 2021 With Over 130 Million Needles and Syringes Delivered

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

iRemedy announced that in association with the Company’s effort to procure and deliver one billion FDA-approved hypodermic needles and syringes in support of COVID-19 vaccination programs worldwide, over 130 million units have been delivered to customers since announcing its program in November 2020.

iRemedy notes having titled this initiative “Project Vaccinate,” they delivered over 30 million units in late 2020 and nearly 100 million units in the first six weeks of 2021 in association with its trusted partner, Northfield Logistics.

With the initiative continuing to gain traction, it is expected that demand for the one billion needles and syringes procured by iRemedy last Fall will exhaust its supply on or before August 2021. Consequently, the Company is in the process of negotiating greater production capacity with its factory partners to maintain continuity of supply to meet growing global need for high quality injection devices for administering COVID-19 vaccinations, flu shots and other critical medicines.

Additionally, in response to growing global demand for “low-dead space” syringes, iRemedy has procured production of 150 million units, taking delivery of approximately 50 million per week — most of which are presold prior to their arrival. Late last month, Reuters reported that the vaccine made by Pfizer and its German partner BioNTech is shipped in vials initially indicated to hold five doses. However, six doses can be drawn with low-dead space syringes, which minimize the amount of vaccine left in the syringe after use. The article states, “If healthcare providers can reliably extract the sixth dose, it would allow supplies to be stretched 20% further…”

“Since the onset of the global pandemic, iRemedy has continued to be broadly viewed as a trusted source for quality PPE products, rapid COVID test kits, and now needles and syringes,” stated Tony Paquin, Co-founder and Chief Executive Officer of iRemedy. “We do not bear this responsibility lightly.”

He concluded, “We are helping to save lives and will do everything within our power to ensure that frontline healthcare providers have the tools and equipment they require to battle the virus when and where they need them. Every member of the iRemedy team shares in this responsibility and takes tremendous pride in the role we are individually and collectively playing in the medical crisis that is proving unprecedented in our lifetime.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

ArisGlobal Reports | Newest Version of LifeSphere® Regulatory Platform Launches

Ann-Marie Orange, CIO & Global Head of R&D shares, “With more than 35 years of experience in life sciences technology, ArisGlobal is the only technology company offering strong Safety, Regulatory, and Quality Management solutions powered with next-generation cognitive computing, delivering unmatched interoperability across the R&D IT ecosystem. Over the last 18 months ArisGlobal has made significant investment in the strategic acquisitions of Amplexor Life Sciences and SPORIFY, along with technology R&D – and we’re not stopping.”